Enzymatica
2.93
SEK
-3.3 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-3.3%
-16.29%
+99.32%
+85.44%
+67.43%
+9.64%
-32.99%
-71.31%
-48.71%
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Read moreMarket cap
711.21M SEK
Turnover
41.63K SEK
Revenue
45.58M
EBIT %
-114.22 %
P/E
-
Dividend yield-%
-
Financial calendar
17/7
2025
Interim report Q2'25
30/10
2025
Interim report Q3'25
18/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
BioStock: The science behind ColdZyme – Insights from professors
Kommuniké från årsstämma i Enzymatica AB (publ) den 7 maj 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools